Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial.

Epilepsia · 2026 · PMC13360963 · PMID 41902639

Europe PMC DOI

hedged sentences

0.0900

closest p · 1.8× alpha

0.1400

boldest claim

The sentences

did not achieve significancep = .09so close (0.05 < p ≤ 0.1)

Regarding seizure frequency, DBS produced a median reduction of 44% (range = −66.66 to 0), whereas BMT resulted in a median reduction of 5.95% (range = −56.10 to 19.64); this between‐group comparison approached but did not achieve significance ( p = .09).

also in 1,397 other papers

did not reach statistical significancep = .14not close (p > 0.1)

3.2 Efficacy At the 12‐month follow‐up (see Table 2 ), the proportion of responders was higher in the DBS group (44.83%, 95% confidence interval [CI] = 26.4–64.3) compared with the BMT group (26.67%, 95% CI = 12.3–45.9), but the difference did not reach statistical significance ( p = .14).

also in 111,027 other papers

showed a trendno p-value reported

Temporal or bitemporal onset cases (± insular involvement) showed a trend toward better outcomes in the DBS group (3/6) than in the BMT group (3/10), although the difference did not reach statistical significance ( p = .23). 3.4 Effects on QoL The secondary outcomes focused particularly on QoL (see Table 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.